The Effect of Radiotherapy Technique on Carotid Artery Dose in Patients with Early Stage Glottic Larynx Cancer
Abstract
Objective: The
aim of this study was to compare two radiotherapy techniques in early stage
glottic laryngeal cancer patients in terms of radiotherapy dose applied to the
carotid artery.
Material - Methods: In this study, we included 10 early-stage (T1/2) glottic larynx cancer patients. Both intensity-modulated radiotherapy (IMRT) and 3-dimension conformal radiotherapy (3DCRT) treatment plans were prepared for each patient. Treatment volumes (CTV, PTV) were created for all patients. The entire larynx was described as CTV to include both false and true vocal cords, anterior-posterior commissures, arytenoids, aryepiglottic folds, subglottic region. For planning target volüme (PTV), while 5-mm was added to CTV in all directions, 3-mm margin was given to protect the carotid artery and spinal cord in posterolaterally. Spinal cord and carotid artery were contoured as the organ at risk (OAR). The doses of the target volumes, the OAR volumes, the homogeneity index (HI) were compared.
Results: PTV parameters (Dmin, Dmean, Dmax, D90, D95) was compared in the 2 different technique. IMRT in comparison to 3DCRT significantly reduced the high-dose volumes (V30, V35, V50) of carotid artery (p < 0.001), but not to the low dose volume (V10). CI was similar (0.9 vs. 0.9, p = 0.3) compared to 3DCRT. However, HI was significantly improved with IMRT (0.1 vs. 0.08, p < 0.001). The maximum dose of the spinal cord was lower in 3DCRT compared to IMRT (18 Gy vs. 44Gy).
Conclusion: IMRT is a superior radiotherapy (RT) technique in patients with T1/T2 glottic cancer in terms of protecting carotid artery.
Keywords
References
- 1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. 2017;3(4):524-48.
- 2. Cantürk E, Topgül G, Gürler O, Tunç S, Abakay CD, Kurt M, et al. Evre I larinks kanseri tedavisinde 3 ve 5 Alan Yoğunluk Ayarlı Radyoterapi (3A-YART, 5A-YART) tekniklerinde karotis arterin dozimetrik olarak karşılaştırılması. 2017;19(3):141-6.
- 3. Piccirillo JFJTL. Importance of comorbidity in head and neck cancer. 2000;110(4):593-602.
- 4. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. 2006;116(S111):1-13.
- 5. Waldfahrer F, Hauptmann B, Iro HJL-r-o. Lymph node metastasis of glottic laryngeal carcinoma. 2005;84(2):96-100.
- 6. Marshak G, Brenner B, Shvero J, Shapira J, Ophir D, Hochman I, et al. Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. 1999;43(5):1009-13.
- 7. Tamura Y, Tanaka S, Asato R, Hirano S, Yamashita M, Tamaki H, et al. Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years. 2007;127(sup557):62-5.
- 8. Aaltonen L-M, Rautiainen N, Sellman J, Saarilahti K, Mäkitie A, Rihkanen H, et al. Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy. 2014;90(2):255-60.
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
Research Article
Publication Date
March 11, 2021
Submission Date
September 23, 2019
Acceptance Date
December 20, 2019
Published in Issue
Year 2021 Volume: 28 Number: 1